At least an outcome of designing the trial to meet FDA's request was a very solid result in the liver, I anticipate the oncology community will respond well to this finding and the p value will be well received. SirSpheres clearly have efficacy in first line in their target organ. A recommendation in NCCN or ESMO guidelines would be nice, but may have to wait for OS data to get this. Expecting dose sales for earlier line should still kick upwards in the meantime on the back of SIRFLOX results, if clinicians wish to control the liver disease they now have level 1 evidence that SirSpheres can help achieve this.
- Forums
- ASX - By Stock
- Potential Market
At least an outcome of designing the trial to meet FDA's request...
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SRX (ASX) to my watchlist
(20min delay)
|
|||||
Last
17.5¢ |
Change
0.005(2.94%) |
Mkt cap ! $74.27M |
Open | High | Low | Value | Volume |
17.5¢ | 18.0¢ | 17.5¢ | $326.7K | 1.850M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 481601 | 17.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
18.0¢ | 2315334 | 24 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 481601 | 0.175 |
9 | 10298718 | 0.170 |
1 | 18186 | 0.165 |
1 | 100000 | 0.160 |
2 | 398596 | 0.155 |
Price($) | Vol. | No. |
---|---|---|
0.180 | 2315334 | 24 |
0.185 | 106315 | 5 |
0.190 | 4906 | 4 |
0.195 | 509604 | 3 |
0.200 | 439974 | 11 |
Last trade - 15.39pm 07/08/2024 (20 minute delay) ? |
Featured News
SRX (ASX) Chart |